IBEX 3519.384,70▲ +0,32%EuroStoxx 506269,97▼ -0,23%S&P 5007575,39▲ +0,42%€/$1,1419▼ -0,13%Brent76,01▼ -0,38%Bitcoin56.069▲ +0,36%

Breaking

The Treasury concludes July with auctions of bills, bonds and obligationsSEPE launches 50,000 grants of up to 8,000 euros to hire over 45sCongress approves pathway to RETA for 47,000 mutualists with pensions of 400 eurosGold falls 1.43% weighed down by the Fed's aggressive shift anticipating rate hikesOutlook Therapeutics: FDA to Decide on Eye Drug Lytenava on July 29Anthropic reaches $200 billion valuation, surpassing OpenAI as the most valuable AI startupThe Treasury concludes July with auctions of bills, bonds and obligationsSEPE launches 50,000 grants of up to 8,000 euros to hire over 45sCongress approves pathway to RETA for 47,000 mutualists with pensions of 400 eurosGold falls 1.43% weighed down by the Fed's aggressive shift anticipating rate hikesOutlook Therapeutics: FDA to Decide on Eye Drug Lytenava on July 29Anthropic reaches $200 billion valuation, surpassing OpenAI as the most valuable AI startup

Biotechnology

Latest biotechnology news

1 article

Primer plano de un frasco de colirio oftalmológico con un calendario borroso al fondo

Companies

Outlook Therapeutics: FDA to Decide on Eye Drug Lytenava on July 29

Outlook Therapeutics faces a pivotal July: shareholders vote on capital increase on the 16th and FDA decides on Lytenava on the 29th.

Beatriz Lorenzo Aguirre · 12 July 2026